Recurrent and chronic dermatophytosis: culprit- not just antifungal resistance

Shruti Appannavar, Kiran ., Gajanan Pise, Rohith ., Ashwini P., Vinitha Sanagoudar, Shradha Gurudev


Background: Recurrent and chronic dermatophytosis is being increasingly seen nowadays. Without drug susceptibility tests, it is difficult to say whether these are due to antifungal resistance or due to other factors.

Methods: Hundred dermatophytosis patients, lasting for more than 6 months were enrolled. Detailed history was taken. A clinical examination and KOH preparation was done.

Results: Out of total 100 patients, male to female ratio was 61:39. The most common age group was 16-30 years and 31-45years respectively. Tinea cruris with corporis was the common clinical type (44%) followed by tinea cruris alone (31%) and tinea corporis alone (25%). KOH was positive in 64%. History of delay in consulting doctor was present in 77%, home remedies in 19%, OTC drug usage in 46% among which 69.56% were steroid combined antifungals, treatment by non dermatologists in 52%. Adherence to therapy was seen only in 28%. The common aggravating factors were hot environment (60%), friction, occlusion and during menstruation. Family history of tinea was positive in 66%. No of baths were less than one per day in 8%, sharing of soap and clothing was seen in 41%.

Conclusions: Misuse of OTC topical corticosteroids, multiple familial contacts, unhygienic practices, treatment by nondermatologists with inappropriate drug, dose and duration, poor compliance to treatment have all contributed to the emergence of chronic and recurrent dermatophytosis.


Dermatophytosis, Resistance, OTC drugs, Steroid creams

Full Text:



Ardeshna KP, Rohatgi S, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol Venereol Leprol. 2016;82:579-82.

Rajagopalan M, Inamadar A, Mittal A. Expert consensus on the management of dermatophytosis in India. BMC Dermatol. 2018;18:6.

Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India : Is the problem deeper than we perceive?. Indian Dermatol J. 2016; 7(2):73-6.

Pathania S, Rudramurthy SM, Narang T, Saikia UN, Dogra S. A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. Indian J Dermatol Venereol Leprol. 2018;84:678-84

Sharma R, Adhikari L, Sharma RL. Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. Indian J Pathol Microbiol. 2017;60:541-5.

Bhatia VK, Sharma PC. Epidemiological studies on dermatophytosis in human patients in Himachal Pradesh, India. Springerplus. 2014;3:134.

Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(4):2-15.

De Freitas RS, Neves PS, Charbel CE, Criado PR, Nunes RS, Santos-Filho AM, et al. Investigation of superficial mycosis in cutaneous allergy patients using topical or systemic corticosteroids. Int J Dermatol. 2017;56:e194-8.

Hanumanthappa H, Sarojini K, Shilpashree P, Muddapur SB. Clinicomycological study of 150 cases of dermatophytosis in a tertiary care hospital in South India. Indian J Dermatol. 2012;57: 322-3.

Bindu V, Pavithran K. Clinico-mycological study of dermatophytosis in Calicut. Indian J Dermatol Venereol Leprol. 2002;68:259-61.